Carboplatin/gemcitabine as first line treatment of metastatic triple negative breast cancer /
Ahmad Mahrous Dewidar
Carboplatin/gemcitabine as first line treatment of metastatic triple negative breast cancer / علاج سرطان الثدي السلبي الثلاثي المنتشر باستخدام عقاري الجيمسيتابين/كاربوبلاتين كخط علاج أول Ahmad Mahrous Dewidar ; Supervised Mohammad Ahmad Hassan , Mohammad Sayed Abdelkader , Wael Samir Makar - Cairo : Ahmad Mahrous Dewidar , 2015 - 72 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology (clinical)
Background and objectives: Triple-negative breast cancer is regarded as an aggressive disease for which effective targeted therapy is not yet available. Results: Among the 34 included patients , 33 were considered valuable for response as one patient refused to continue treatment after she received the first week of treatment due to grade 3 vomiting, four patients (12.1%) achieved complete response and 20 patients (60.6%) had a partial response giving an overall response rate of 72.7% (95% CI, 60%-84%), one patients(3%) had stable disease > 6 months giving clinical benefit rate(CBR) of 75.7% (25/٣٣). The median duration of response of 6.5 months. while 8 cases progressed in treatment (24.7%), Median progression-free survival, was 6.18 months (95% CI 5.617·30 ) .Overall survival was 12.7month (range2-24, SD: 5.1) . Neutropenia G3 in 3 patients(9%) one of them developed febrile neutropenia ,anemia grade three in 4\33 patients(12%), thrombocytopenia grade 3 in 5 patinets (15%). Conclusions:. This study suggested that The combination was efficacious and well tolerated
Breast cancer Metastatic Triple negative
Carboplatin/gemcitabine as first line treatment of metastatic triple negative breast cancer / علاج سرطان الثدي السلبي الثلاثي المنتشر باستخدام عقاري الجيمسيتابين/كاربوبلاتين كخط علاج أول Ahmad Mahrous Dewidar ; Supervised Mohammad Ahmad Hassan , Mohammad Sayed Abdelkader , Wael Samir Makar - Cairo : Ahmad Mahrous Dewidar , 2015 - 72 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology (clinical)
Background and objectives: Triple-negative breast cancer is regarded as an aggressive disease for which effective targeted therapy is not yet available. Results: Among the 34 included patients , 33 were considered valuable for response as one patient refused to continue treatment after she received the first week of treatment due to grade 3 vomiting, four patients (12.1%) achieved complete response and 20 patients (60.6%) had a partial response giving an overall response rate of 72.7% (95% CI, 60%-84%), one patients(3%) had stable disease > 6 months giving clinical benefit rate(CBR) of 75.7% (25/٣٣). The median duration of response of 6.5 months. while 8 cases progressed in treatment (24.7%), Median progression-free survival, was 6.18 months (95% CI 5.617·30 ) .Overall survival was 12.7month (range2-24, SD: 5.1) . Neutropenia G3 in 3 patients(9%) one of them developed febrile neutropenia ,anemia grade three in 4\33 patients(12%), thrombocytopenia grade 3 in 5 patinets (15%). Conclusions:. This study suggested that The combination was efficacious and well tolerated
Breast cancer Metastatic Triple negative